



US009439901B2

(12) **United States Patent**  
**Mascitti**(10) **Patent No.:** **US 9,439,901 B2**  
(45) **Date of Patent:** **Sep. 13, 2016**(54) **DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES**(71) Applicant: **Pfizer Inc.**, New York, NY (US)(72) Inventor: **Vincent Mascitti**, Groton, CT (US)(73) Assignee: **Pfizer Inc.**, New York, NY (US)

( \* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/535,556**(22) Filed: **Nov. 7, 2014**(65) **Prior Publication Data**

US 2015/0065512 A1 Mar. 5, 2015

**Related U.S. Application Data**

(60) Division of application No. 13/796,339, filed on Mar. 12, 2013, now abandoned, which is a continuation of application No. 13/498,702, filed as application No. PCT/IB2010/054775 on Oct. 21, 2010, now Pat. No. 8,669,380.

(60) Provisional application No. 61/372,938, filed on Aug. 12, 2010, provisional application No. 61/257,140, filed on Nov. 2, 2009.

(51) **Int. Cl.****A61K 31/357** (2006.01)**A61K 31/155** (2006.01)**C07D 493/08** (2006.01)**A61K 31/4985** (2006.01)**A61K 45/06** (2006.01)(52) **U.S. Cl.**CPC ..... **A61K 31/4985** (2013.01); **A61K 31/155** (2013.01); **A61K 31/357** (2013.01); **A61K 45/06** (2013.01); **C07D 493/08** (2013.01)(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

3,174,901 A 3/1965 Sterne  
 4,598,089 A 7/1986 Hadvary et al.  
 4,929,629 A 5/1990 Jeffrey  
 5,047,518 A 9/1991 Furneaux et al.  
 5,591,836 A 1/1997 Mazur et al.  
 5,624,941 A 4/1997 Barth et al.  
 6,069,238 A 5/2000 Hitchcock et al.  
 6,414,126 B1 7/2002 Ellsworth et al.  
 6,486,299 B1 11/2002 Shimkets  
 6,515,117 B2 2/2003 Ellsworth et al.  
 6,555,519 B2 4/2003 Washburn  
 6,627,611 B2 9/2003 Tomiyama et al.  
 6,683,056 B2 1/2004 Washburn et al.  
 6,774,112 B2 8/2004 Gougoutas  
 6,815,428 B2 11/2004 Ohsumi et al.  
 6,838,442 B2 1/2005 Bussolari et al.  
 6,872,706 B2 3/2005 Fujikura et al.  
 6,908,905 B2 6/2005 Ohsumi et al.

6,936,590 B2 8/2005 Washburn et al.

6,972,283 B2 12/2005 Fujikura et al.

7,045,665 B2 5/2006 Fujikura et al.

7,053,060 B2 5/2006 Fujikura et al.

7,056,892 B2 6/2006 Fujikura et al.

7,084,123 B2 8/2006 Fujikura et al.

7,087,579 B2 8/2006 Nishimura et al.

7,101,856 B2 9/2006 Glombik et al.

7,169,761 B2 1/2007 Tomiyama et al.

7,202,350 B2 4/2007 Imamura et al.

7,217,697 B2 5/2007 Shiohara et al.

7,247,705 B2 7/2007 Iwamoto et al.

7,250,522 B2 7/2007 Sato et al.

(Continued)

**FOREIGN PATENT DOCUMENTS**CA 2572149 1/2006  
CA 2666375 9/2007

(Continued)



**OTHER PUBLICATIONS**

Ehrenkranz, et al., "Phlorizin: a review", Diabetes/Metabolism Research and Reviews, vol. 21(1), pp. 31-38 (2005).

(Continued)

*Primary Examiner* — San-Ming Hui*Assistant Examiner* — Andrew Lee(74) *Attorney, Agent, or Firm* — Lisa A. Samuels(57) **ABSTRACT**

Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

**2 Claims, No Drawings**